Importer of Controlled Substances; Notice of Application, 46227-46228 [E9-21543]
Download as PDF
<![CDATA[
46227
Federal Register / Vol. 74, No. 172 / Tuesday, September 8, 2009 / Notices
jlentini on DSKJ8SOYB1PROD with NOTICES
additional information, please contact:
Amy Callaghan, (202) 514–9292, Office
of Audit, Assessment, and Management,
Office of Justice Programs, U.S.
Department of Justice, 810 Seventh
Street, NW., Washington, DC 20531 or
Amy.Callaghan@usdoj.gov.
Written comments and suggestions
from the public and affected parties
concerning the proposed collection of
information are encouraged. Your
comments should address one or more
of the following four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
—Evaluate the accuracy of the agency’s
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Enhance the quality, utility, and
clarity of the information to be
collected; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
Overview of This Information
(1) Type of information collection:
Information in response to the required
data elements outlined in the
solicitation template for programs
administered by the Office of Justice
Programs.
(2) The title of the form/collection:
Office of Justice Programs solicitation
template.
(3) The agency form number, if any,
and the applicable component of the
Department sponsoring the collection:
The Office of Audit, Assessment, and
Management, Office of Justice Programs,
U.S. Department of Justice.
(4) Affected public who will be asked
or required to respond, as well as a brief
abstract: State agencies, tribal
governments, local governments,
colleges and universities, non-profit
organizations, for-profit organizations
and faith-based organizations. The
purpose of the solicitation template is to
provide framework to develop programspecific announcements soliciting
applications for funding. A program
solicitation outlines the specifics of the
funding program; describes
requirements for eligibility; instructs an
applicant on the necessary components
of an application under a specific
VerDate Nov<24>2008
17:32 Sep 04, 2009
Jkt 217001
program (e.g, project activities and
timeline, proposed budget); outlines
program evaluation and performance
measure; explains selection criteria and
the review process; and provides
registration dates, due dates, and
instructions on how to apply within the
designated application system.
(5) An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond/reply: It is estimated that
information will be collected annually
from 9,800 applicants, representing
State agencies, tribal governments, local
governments, colleges and universities,
non-profit organizations, and for-profit
organizations. Annual cost to the
respondents is based on the number of
hours involved in preparing and
submitting a complete application
package. Public reporting burden for
this collection of information is
estimated at up to 30 hours per
application. The 30-hour estimate is
based on the amount of time to prepare
research and evaluation proposals, one
of the most time intensive types of
applications solicited by OJP. The
estimate of burden hours is based on
OJP’s prior experience with the research
application submissions process.
(6) An estimate of the total public
burden (in hours) associated with the
collection: The estimated public burden
associated with this collection is
294,000 hours.
If additional information is required
contact: Mrs. Lynn Bryant, Department
Clearance Officer, United States
Department of Justice, Justice
Management Division, Policy and
Planning Staff, Suite 1600, 601 D Street,
NW., Washington, DC 20530.
Dated: September 1, 2009.
Lynn Bryant,
Department Clearance Officer, PRA, U.S.
Department of Justice.
[FR Doc. E9–21514 Filed 9–4–09; 8:45 am]
BILLING CODE 4410–18–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
PO 00000
Frm 00148
Fmt 4703
Sfmt 4703
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations (CFR),
1301.34(a), this is notice that on July 16,
2009, Cerilliant Corporation, 811
Paloma Drive, Suite A, Round Rock,
Texas 78665–2402, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the basic classes of
controlled substances listed in
schedules I and II:
Drug
Cathinone (1235) ..........................
Methcathinone (1237) ..................
N–Ethylamphetamine (1475) ........
N,N–Dimethylamphetamine
(1480).
Fenethylline (1503) .......................
Gamma
Hydroxybutyric
Acid
(2010).
Ibogaine (7260) ............................
Lysergic acid diethylamide (7315)
2,5-Dimethoxy-4-(n)propylthiophenethylamine
(7348).
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Mescaline (7381) ..........................
3,4,5-Trimethoxyamphetamine
(7390).
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
4-Methyl-2,5dimethoxyamphetamine (7395).
2,5-Dimethoxyamphetamine
(7396).
3,4-Methylenedioxyamphetamine
(7400).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4-Methylenedioxymethamphetamine (7405).
4-Methoxyamphetamine (7411) ...
Alpha-methyltryptamine (7432) ....
Diethyltryptamine (7434) ..............
Dimethyltryptamine (7435) ...........
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
N-Benzylpiperazine (7493) ...........
Etorphine (except HCl) (9056) .....
Heroin (9200) ...............................
Morphine-N-oxide (9307) .............
Normorphine (9313) .....................
Pholcodine (9314) ........................
Dextromoramide (9613) ...............
Dipipanone (9622) ........................
Trimeperidine (9646) ....................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Methylphenidate (1724) ................
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Phencyclidine (7471) ....................
Phenylacetone (8501) ..................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
E:\FR\FM\08SEN1.SGM
08SEN1
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
46228
Federal Register / Vol. 74, No. 172 / Tuesday, September 8, 2009 / Notices
Schedule
Drug
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Benzoylecgonine (9180) ...............
Ethylmorphine (9190) ...................
Meperidine (9230) ........................
Methadone (9250) ........................
Dextropropoxyphene, bulk (nondosage forms).
(9273) ...........................................
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Levo-alphacetylmethadol (9648) ..
Oxymorphone (9652) ...................
Poppy Straw Concentrate (9670)
Fentanyl (9801) ............................
DEPARTMENT OF JUSTICE
II
II
II
II
II
II
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
II
II
II
II
II
II
II
II
jlentini on DSKJ8SOYB1PROD with NOTICES
The company plans to import small
quantities of the listed controlled
substances for the manufacture of
analytical reference standards.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances may file comments or
objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43, and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than October 8, 2009.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance listed in
schedule I or II are, and will continue
to be, required to demonstrate to the
Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: August 28, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–21543 Filed 9–4–09; 8:45 am]
BILLING CODE 4410–09–P
VerDate Nov<24>2008
17:32 Sep 04, 2009
Jkt 217001
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations (CFR),
1301.34(a), this is notice that on July 8,
2009, Clinical Supplies Management,
Inc., 342 42nd Street South, Fargo,
North Dakota 58103, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of Sufentanil (9740), a basic
class of controlled substance listed in
schedule II.
The company plans to import the
listed controlled substance with the sole
purpose of packaging, labeling, and
distributing to customers which are
qualified clinical sites conducting
clinical trials under the auspices of an
FDA-approved clinical study.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, VA 22152; and must be
filed no later than October 8, 2009.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are and will continue to be required
to demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, that the requirements
PO 00000
Frm 00149
Fmt 4703
Sfmt 4703
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: August 28, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–21541 Filed 9–4–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations (CFR),
1301.34(a), this is notice that on July 2,
2009, GE Healthcare, 3350 North Ridge
Avenue, Arlington Heights, Illinois
60004–1412, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of Cocaine (9041), a basic
class of controlled substance listed in
schedule II.
The company plans to import small
quantities of ioflupane, in the form of
three separate analogues of Cocaine, to
validate production and quality control
systems, for a reference standard, and
for producing material for a future
investigational new drug (IND)
submission.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, VA. 22152; and must be
filed no later than October 8, 2009.
E:\FR\FM\08SEN1.SGM
08SEN1
]]>Agencies
[Federal Register Volume 74, Number 172 (Tuesday, September 8, 2009)]
[Notices]
[Pages 46227-46228]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-21543]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this Section to a bulk manufacturer of a
controlled substance in schedule I or II, and prior to issuing a
regulation under 21 U.S.C. 952(a)(2) authorizing the importation of
such a substance, provide manufacturers holding registrations for the
bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with Title 21 Code of Federal Regulations
(CFR), 1301.34(a), this is notice that on July 16, 2009, Cerilliant
Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78665-2402,
made application by renewal to the Drug Enforcement Administration
(DEA) to be registered as an importer of the basic classes of
controlled substances listed in schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Cathinone (1235)........................... I
Methcathinone (1237)....................... I
N-Ethylamphetamine (1475).................. I
N,N-Dimethylamphetamine (1480)............. I
Fenethylline (1503)........................ I
Gamma Hydroxybutyric Acid (2010)........... I
Ibogaine (7260)............................ I
Lysergic acid diethylamide (7315).......... I
2,5-Dimethoxy-4-(n)- I
propylthiophenethylamine (7348).
Marihuana (7360)........................... I
Tetrahydrocannabinols (7370)............... I
Mescaline (7381)........................... I
3,4,5-Trimethoxyamphetamine (7390)......... I
4-Bromo-2,5-dimethoxyamphetamine (7391).... I
4-Bromo-2,5-dimethoxyphenethylamine (7392). I
4-Methyl-2,5-dimethoxyamphetamine (7395)... I
2,5-Dimethoxyamphetamine (7396)............ I
3,4-Methylenedioxyamphetamine (7400)....... I
3,4-Methylenedioxy-N-ethylamphetamine I
(7404).
3,4-Methylenedioxy- methamphetamine (7405). I
4-Methoxyamphetamine (7411)................ I
Alpha-methyltryptamine (7432).............. I
Diethyltryptamine (7434)................... I
Dimethyltryptamine (7435).................. I
Psilocybin (7437).......................... I
Psilocyn (7438)............................ I
N-Benzylpiperazine (7493).................. I
Etorphine (except HCl) (9056).............. I
Heroin (9200).............................. I
Morphine-N-oxide (9307).................... I
Normorphine (9313)......................... I
Pholcodine (9314).......................... I
Dextromoramide (9613)...................... I
Dipipanone (9622).......................... I
Trimeperidine (9646)....................... I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Methylphenidate (1724)..................... II
Amobarbital (2125)......................... II
Pentobarbital (2270)....................... II
Secobarbital (2315)........................ II
Phencyclidine (7471)....................... II
Phenylacetone (8501)....................... II
Cocaine (9041)............................. II
Codeine (9050)............................. II
Dihydrocodeine (9120)...................... II
[[Page 46228]]
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Benzoylecgonine (9180)..................... II
Ethylmorphine (9190)....................... II
Meperidine (9230).......................... II
Methadone (9250)........................... II
Dextropropoxyphene, bulk (non-dosage forms)
(9273)..................................... II
Morphine (9300)............................ II
Oripavine (9330)........................... II
Thebaine (9333)............................ II
Levo-alphacetylmethadol (9648)............. II
Oxymorphone (9652)......................... II
Poppy Straw Concentrate (9670)............. II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to import small quantities of the listed
controlled substances for the manufacture of analytical reference
standards.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic classes of controlled
substances may file comments or objections to the issuance of the
proposed registration and may, at the same time, file a written request
for a hearing on such application pursuant to 21 CFR 1301.43, and in
such form as prescribed by 21 CFR 1316.47.
Any such comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than October 8, 2009.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b), (c),
(d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, (40 FR 43745-46), all
applicants for registration to import a basic class of any controlled
substance listed in schedule I or II are, and will continue to be,
required to demonstrate to the Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement Administration, that the
requirements for such registration pursuant to 21 U.S.C. 958(a); 21
U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: August 28, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E9-21543 Filed 9-4-09; 8:45 am]
BILLING CODE 4410-09-P
